Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tanacetum cinerariifolium flower extract is an allergenic extract derived from the Dalmatian pyrethrum plant, used primarily as a diagnostic agent in allergy testing. Approved in the United States in 1965 under BLA 103753, the extract is employed in skin prick or intradermal testing to identify individuals with hypersensitivity to pyrethrum or chrysanthemum allergens. The diagnostic procedure relies on the extract's ability to cross-link allergen-specific IgE on mast cells, inducing a localized inflammatory response (wheal and flare) in sensitive patients. This testing is clinically significant for diagnosing the cause of allergic dermatitis, rhinitis, and asthma in individuals exposed to pyrethrum-containing products or the plant itself.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tanacetum cinerariifolium flower extract.